Predictive Oncology Sets Pricing for Private Placements to Launch Digital Asset Treasury
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 29 2025
0mins
Should l Buy ?
Investment Overview: The Company plans to raise approximately $344.4 million through two private investment transactions, involving the sale of around 66.7 million shares of common stock at $0.7751 per share and pre-funded warrants for up to 223.6 million shares.
Use of Proceeds: The funds will be used to support the Company's digital asset treasury strategy, acquire ATH tokens in the open market, and for general working capital and corporate purposes, with DNA Holdings Venture, Inc. acting as a strategic advisor.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
